Robotic assisted CyberKnife radiosurgery for the treatment of iris melanoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
11 03 2021
11 03 2021
Historique:
received:
04
07
2020
accepted:
16
10
2020
entrez:
12
3
2021
pubmed:
13
3
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Iris melanoma is a rare form of uveal melanoma with potential metastic spread. Treatment options include surgical resection, enucleation or irradiation. We analysed visual outcome, complication appearance and management in eight patients with iris melanoma following robotic-assisted CyberKnife treatment. Consecutive patients from the Department of Ophthalmology at University of Munich were included in the study if they had an iris melanoma that was treated with CyberKnife and had a minimum follow-up of 12 months. We evaluated tumor thickness, largest diameter, visual acuity and complications. 8 patients were included in this report. The median age was 74 years (range: 53-86 years). The median follow-up was 23 months (range 12-48 months). Tumor thickness decreased from 2.1 to 1.4 mm on average. Four out of eight patients showed stable or increased visual acuity compared to visual acuity at first visit. We did not find a correlation of applied radiation volume or radiation dose on visual outcome. Radiation keratopathy was the most common complication in five patients. No recurrences were noted. Robotic-assisted radiosurgery following CyberKnife is a promising non-invasive, single session treatment option for iris melanoma with comparable results regarding recurrence rate or complications to brachytherapy and proton beam therapy. All included patients showed good visual outcome.
Identifiants
pubmed: 33707492
doi: 10.1038/s41598-021-84290-x
pii: 10.1038/s41598-021-84290-x
pmc: PMC7952409
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5685Références
Ophthalmology. 2018 Apr;125(4):606-614
pubmed: 29128229
Br J Ophthalmol. 2018 Aug;102(8):1154-1159
pubmed: 29122824
Ophthalmology. 2018 Jun;125(6):913-923
pubmed: 29342436
Acta Ophthalmol. 2012 May;90(3):291-6
pubmed: 20670343
Strahlenther Onkol. 2017 Nov;193(11):943-950
pubmed: 28631017
Int J Cancer. 1995 Mar 3;60(5):622-6
pubmed: 7860135
Eye (Lond). 2011 Dec;25(12):1607-11
pubmed: 21941358
Acta Ophthalmol. 2012 Mar;90(2):122-6
pubmed: 20456258
Br J Ophthalmol. 2014 Jan;98(1):92-8
pubmed: 24169654
Am J Ophthalmol. 2010 Jan;149(1):70-6
pubmed: 19892312
Br J Ophthalmol. 2014 Apr;98(4):484-7
pubmed: 24414401
Ophthalmology. 2012 Apr;119(4):838-842.e2
pubmed: 22133794
Br J Ophthalmol. 2015 Jun;99(6):812-6
pubmed: 25505288
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1361-6
pubmed: 21665382
Ophthalmology. 2012 Feb;119(2):407-14
pubmed: 22035581
Ophthalmology. 2013 Jan;120(1):55-61
pubmed: 22980742
Melanoma Res. 2020 Jun;30(3):309-312
pubmed: 30730329
Br J Ophthalmol. 2018 Jan;102(1):74-78
pubmed: 28600302
Ophthalmology. 2013 Apr;120(4):766-72
pubmed: 23290981
Surv Ophthalmol. 2017 May - Jun;62(3):302-311
pubmed: 28062196
Br J Ophthalmol. 2011 Oct;95(10):1474-6
pubmed: 21719566
Graefes Arch Clin Exp Ophthalmol. 2014 Sep;252(9):1515-21
pubmed: 25038910
Ophthalmology. 2001 Jan;108(1):172-8
pubmed: 11150284
Am J Ophthalmol. 2012 Jun;153(6):1043-9
pubmed: 22321804
Technol Cancer Res Treat. 2008 Oct;7(5):369-74
pubmed: 18783286
Ophthalmology. 1988 Sep;95(9):1251-5
pubmed: 3211503
Retina. 2012 Jul;32(7):1363-72
pubmed: 22466491
Doc Ophthalmol. 1992;82(1-2):49-55
pubmed: 1305027